Many inhalers that are vital for patients with asthma or COPD are associated with societal harms that can worsen the very diseases the products are designed to treat. How can this dilemma be resolved?

Association Between Industry Payments and Prescription of Inhaled Medications

United Health Group’s pharmacy benefit manager, Optum Rx, stopped covering Cole Schmidtknecht’s ‘life-changing’ inhaler, suit alleges.

Patients using a triple combination dry powder inhaler had a slightly lower rate of COPD exacerbations than those using a high-carbon metered-dose inhaler, a retrospective study has found.

Objective To compare the effectiveness and safety of budesonide-glycopyrrolate-formoterol, a twice daily metered dose inhaler, and fluticasone-umeclidinium-vilanterol, a once daily dry powder inhaler,...

The U.S. health care system could reduce emissions from asthma inhalers and mitigate their negative impact on population health.

Objective To compare the effectiveness and safety of budesonide-glycopyrrolate-formoterol, a twice daily metered dose inhaler, and fluticasone-umeclidinium-vilanterol, a once daily dry powder inhaler,...

On Friday, we submitted an amicus brief in Teva vs. Amneal. Teva is suing Amneal for infringing its device-only patents on ProAir HFA (albuterol). This case…

by Dennis Crouch In a major decision clarifying the scope of Orange Book patent listings, the Federal Circuit has ruled …

As various reform ideas are proposed, the organized medical and scientific community will need to work with the new leadership at the FDA to promote positive change–and oppose initiatives that undermi...

Proposed reforms from the U.S. Patent and Trademark Office and Congress could work in tandem to prevent patent thickets by targeting strategies that impede market entry of generic and biosimilar drugs.

Background The development of new infectious disease therapies has become a public health priority given the suboptimal efficacy and adverse effects with current drugs for some patients. Understanding...

Background The development of new infectious disease therapies has become a public health priority given the suboptimal efficacy and adverse effects with current drugs for some patients. Understanding...

This Special Communication analyzes and compares development times, clinical trial success rates, research and development costs, patent protection, market exclusivity periods, revenues, and treatment...

This Special Communication analyzes and compares development times, clinical trial success rates, research and development costs, patent protection, market exclusivity periods, revenues, and treatment...

Audio Interview from the New England Journal of Medicine — Interview with Benjamin Rome on the results of the initial round of drug-price negotiation under the Inflation Reduction Act.

Co-hosts: FDA and the Center for Research on Complex Generics (CRCG) In person (at The Universities at Shady Grove; Rockville, MD) and virtual workshop.

Audio Interview from the New England Journal of Medicine — Interview with Benjamin Rome on the results of the initial round of drug-price negotiation under the Inflation Reduction Act.